(GRCL) – Press Releases
-
AstraZeneca Full year and Q4 2023 Financial Results
-
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases
-
Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update
-
Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65ᵗʰ American Society of Hematology Annual Meeting &
-
Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023
-
Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
-
Gracell Biotechnologies’ CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders
-
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
-
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting
-
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
-
Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update
-
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
-
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
-
Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023
-
Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting
-
Gracell Biotechnologies to Participate in Jefferies Healthcare Conference
-
Gracell Biotechnologies to Host KOL Webinar on Multiple Myeloma on May 22nd
-
Gracell Biotechnologies Reports First Quarter 2023 Unaudited Financial Results, and Provides Corporate Update
-
Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE)
-
Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress
-
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
-
Gracell Biotechnologies to Report First Quarter 2023 Financials on Monday, May 15, 2023
-
Gracell Biotechnologies to Report First Quarter 2023 Financials on Monday, May 15, 2023
-
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F at 2023 ASCO Annual Meeting
-
Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022
-
Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022
-
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
-
Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update
-
Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update
-
Gracell Biotechnologies to Participate in Oppenheimer 33rd Annual Healthcare Conference
-
Gracell Biotechnologies to Report Fourth Quarter 2022 Financials on Monday, March 13, 2023
-
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
-
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
-
Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma
-
Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate
-
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
-
Gracell Biotechnologies Wins 2022 Fierce Life Sciences Innovation Award
-
Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results and Provides Corporate Update
-
Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results and Provides Corporate Update
-
Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition
-
Gracell Biotechnologies to Report Third Quarter 2022 Financials on Monday, November 14, 2022
-
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
-
Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia
-
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
-
Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences
-
Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update
-
Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update
-
Gracell Biotechnologies to Report Second Quarter 2022 Financial on Monday, August 15, 2022
-
Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer
-
Gracell Biotechnologies to Participate in BTIG 2022 Biotechnology Conference
Back to GRCL Stock Lookup
